ARKG

ARK Genomic Revolution ETF (ARKG) | Rumor.io

ARK Genomic Revolution ETF

ARKG

Attention (50-day avg)0.18%

Attention rank (50-day avg)#80

Bullish sentiment (50-day avg)87%

Price to earnings ratio0

Net assets0

Expense ratio0.01%

Social

What share of all ETF conversation is about ARKG?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.25% +0.09	0.24% -0.06	0.17% -0.03	0.02% +0.01

Sep 24

The ARKG ETF has seen significant price increases, with some users predicting it will reach 1,000%+ before expiration.
The genomics theme is performing well, with many names in the ARKG ETF experiencing incredible action, but users are cautious about buying or chasing the trend due to the "drug study" risk.
Users are predicting a potential acquisition of Quantum-Si (QSI) by Anthropic, citing the company's valuable data and the increasing importance of data in biopharma discovery.

Generated by AI

Sentiment

Of the messages about ARKG that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	52.81% -46.13	92.74% -4.15	90.01% +3.35	89.43% +10.42
Bearish	47.19% +46.13	7.26% +4.15	9.99% -3.35	10.57% -10.42

Bullish· Sep 17

The ARKG Genomic Revolution ETF is experiencing a strong breakout, with the stock reaching new highs and showing a 200%+ gain on October 16th.
The ETF's performance is outpacing its peers, with Cathie Wood's leadership and the fund's focus on genomics driving its success, particularly in comparison to the biotech ETF XBI.
The stock's chart is showing a favorable trend, with rising indicators and a strong technical picture, suggesting further bullish continuation.

Bearish· Aug 27

ARKG's performance has been significantly worse than a healthcare mutual fund run by a medical professional, with a 60% loss over 5 years compared to a 10% loss.
Cathie Wood's leadership of ARKG has been questioned due to her aggressive investment approach and lack of expertise in healthcare.
Accumulating losses from ARKG and selling the stock at a loss may be a more effective strategy than holding onto it in hopes of a future recovery.

Generated by AI

Topics

Of the messages about ARKG that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Technical Analysis	100%	100%	99.25%	94.15%
Macro	0%	0%	0.75%	5.85%

Macro· Dec 1

The ARKG ETF is down 40% according to some investors.
One investor believes the current market scenario is similar to 2011, citing tapering as a concern.
Some investors are shorting ARKG, while others are holding on despite significant losses.

Technical Analysis· Aug 19

The genomics sector is experiencing a stage 2 breakout, with the $ARKG ETF reaching a new high and potentially continuing to the next target.
A call buyer is paying a premium of $133K for the $ARKG 47C Aug 28 contract, requiring the price to be above $48.45 within 9 days to breakeven.
The $ARKG ETF is experiencing a bullish breakaway gap, with tons of strength in genomics and biotech, and the sector potentially heading for a more powerful cycle.

Generated by AI

Community

Of the messages about ARKG, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	70.53%	95.19%	69.88%	69.83%
Newcomers	29.47%	4.81%	30.12%	30.17%

Regulars· Aug 19

The regulars are excited about the potential of the genomics sector, with some even considering it a new beginning, as evidenced by the increasing interest in $ARKG and its components.
The 50C Sep 18 option sweep on $ARKG is a notable development, with a significant volume and open interest ratio, indicating a potential price move towards $51.44 breakeven.
The regulars are optimistic about the ETF's performance, with some even considering it a "nice day" and a potential target of $80, while others are looking to take it to $50.00.

Newcomers· Jun 27

Kyle is buying $ARKG, the ARK Genomic Revolution ETF, and sees it breaking out of a four or five year range, with signs of life after being left for dead.
The ARK Genomic Revolution ETF, managed by Cathie Wood, holds a basket of smaller biotech companies at the cutting edge of AI-driven biotech, making it a high-risk, high-reward investment.
Some investors are holding a position in $ARKG, despite its peak inflows in late 2020 and early 2021 when it topped $110, with most retail money being sucked in at the peak.

Generated by AI

News

Cathie Wood's ARK Invest Adds Nvidia Stake, Sells AMD Stock Across Four ETFs

The transactions extend a recent pattern of ARK increasing its exposure to Nvidia while selectively reducing its AMD holdings.

1mo agoYahoo Finance

ARKG: Caught In The Tech Sell-Off, But Here's Why The Dip Is Buyable (BATS:ARKG)

2mo agoSeeking Alpha

Cathie Wood Just Bet Big on This Biotech Stock | The Motley Fool

Ionis Pharmaceuticals' shares are down more than 27% so far this year. What does Cathie Wood see that others are missing?

2mo agoThe Motley Fool

Cathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy? | The Motley Fool

Cathie Wood's Ark Genomic Revolution ETF owns $50 million worth of Recursion Pharmaceuticals stock.

2mo agoThe Motley Fool

Cathie Wood's Ark Invest Sold $7.4 Million of BioNTech Stock | The Motley Fool

Cathie Wood's biotech ETF has largely moved on from the vaccine maker.

2mo agoThe Motley Fool

5 Best Biotech ETFs for 2026 and How to Invest | The Motley Fool

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

2mo agoThe Motley Fool

Also Discussed

Investors talking about ARKG also mention

#	Name	Attention
1	Ark Fintech Innovation ETFARKF	0%0
2	ARK Autonomous Technology & Robotics ETFARKQ	0.29%+0.29
3	ARK Next Generation Internet ETFARKW	0.03%new
4	ARK Innovation ETF FundARKK	0%-0.13
5	ARK Space & Defense Innovation ETFARKX	0.01%new
6	Global X Genomics & Biotechnology ETFGNOM	0.01%+0
7	Pacific Biosciences of California, Inc. Common StockPACB	0%0
8	CRISPR Therapeutics AGCRSP	0%0
9	NVTA - Invitae Corporation	——
10	Twist Bioscience CorporationTWST	0%-0.02

ARK Genomic Revolution ETF

ARK Genomic Revolution ETF is an actively managed exchange-traded fund focused on companies participating in the genomics revolution. ARK Genomic Revolution ETF invests primarily in equity securities across sectors such as health care, information technology, materials, energy, and consumer discretionary, targeting businesses involved in areas like gene editing, bioinformatics, molecular diagnostics, targeted therapeutics, and multiomics innovation. The fund is designed to provide diversified exposure to a fast-evolving part of the healthcare and life sciences ecosystem, where advances in data, diagnostics, and genetic technologies are reshaping how disease is detected and treated. By concentrating on companies tied to genomic innovation, ARK Genomic Revolution ETF serves as a thematic vehicle for investors seeking exposure to the intersection of biotechnology, healthcare, and technology markets.

Location

United States

Social

What share of all ETF conversation is about ARKG?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.25% +0.09	0.24% -0.06	0.17% -0.03	0.02% +0.01

Sep 24

The ARKG ETF has seen significant price increases, with some users predicting it will reach 1,000%+ before expiration.
The genomics theme is performing well, with many names in the ARKG ETF experiencing incredible action, but users are cautious about buying or chasing the trend due to the "drug study" risk.
Users are predicting a potential acquisition of Quantum-Si (QSI) by Anthropic, citing the company's valuable data and the increasing importance of data in biopharma discovery.

Generated by AI

Sentiment

Of the messages about ARKG that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	52.81% -46.13	92.74% -4.15	90.01% +3.35	89.43% +10.42
Bearish	47.19% +46.13	7.26% +4.15	9.99% -3.35	10.57% -10.42

Bullish· Sep 17

The ARKG Genomic Revolution ETF is experiencing a strong breakout, with the stock reaching new highs and showing a 200%+ gain on October 16th.
The ETF's performance is outpacing its peers, with Cathie Wood's leadership and the fund's focus on genomics driving its success, particularly in comparison to the biotech ETF XBI.
The stock's chart is showing a favorable trend, with rising indicators and a strong technical picture, suggesting further bullish continuation.

Bearish· Aug 27

ARKG's performance has been significantly worse than a healthcare mutual fund run by a medical professional, with a 60% loss over 5 years compared to a 10% loss.
Cathie Wood's leadership of ARKG has been questioned due to her aggressive investment approach and lack of expertise in healthcare.
Accumulating losses from ARKG and selling the stock at a loss may be a more effective strategy than holding onto it in hopes of a future recovery.

Generated by AI

Topics

Of the messages about ARKG that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Technical Analysis	100%	100%	99.25%	94.15%
Macro	0%	0%	0.75%	5.85%

Macro· Dec 1

The ARKG ETF is down 40% according to some investors.
One investor believes the current market scenario is similar to 2011, citing tapering as a concern.
Some investors are shorting ARKG, while others are holding on despite significant losses.

Technical Analysis· Aug 19

The genomics sector is experiencing a stage 2 breakout, with the $ARKG ETF reaching a new high and potentially continuing to the next target.
A call buyer is paying a premium of $133K for the $ARKG 47C Aug 28 contract, requiring the price to be above $48.45 within 9 days to breakeven.
The $ARKG ETF is experiencing a bullish breakaway gap, with tons of strength in genomics and biotech, and the sector potentially heading for a more powerful cycle.

Generated by AI

Community

Of the messages about ARKG, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	70.53%	95.19%	69.88%	69.83%
Newcomers	29.47%	4.81%	30.12%	30.17%

Regulars· Aug 19

The regulars are excited about the potential of the genomics sector, with some even considering it a new beginning, as evidenced by the increasing interest in $ARKG and its components.
The 50C Sep 18 option sweep on $ARKG is a notable development, with a significant volume and open interest ratio, indicating a potential price move towards $51.44 breakeven.
The regulars are optimistic about the ETF's performance, with some even considering it a "nice day" and a potential target of $80, while others are looking to take it to $50.00.

Newcomers· Jun 27

Kyle is buying $ARKG, the ARK Genomic Revolution ETF, and sees it breaking out of a four or five year range, with signs of life after being left for dead.
The ARK Genomic Revolution ETF, managed by Cathie Wood, holds a basket of smaller biotech companies at the cutting edge of AI-driven biotech, making it a high-risk, high-reward investment.
Some investors are holding a position in $ARKG, despite its peak inflows in late 2020 and early 2021 when it topped $110, with most retail money being sucked in at the peak.

Generated by AI

ARK Genomic Revolution ETF

Social

Sep 24

Bullish· Sep 17

Bearish· Aug 27

Macro· Dec 1

Technical Analysis· Aug 19

Regulars· Aug 19

Newcomers· Jun 27

Cathie Wood's ARK Invest Adds Nvidia Stake, Sells AMD Stock Across Four ETFs

ARKG: Caught In The Tech Sell-Off, But Here's Why The Dip Is Buyable (BATS:ARKG)

Cathie Wood Just Bet Big on This Biotech Stock | The Motley Fool

Cathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy? | The Motley Fool

Cathie Wood's Ark Invest Sold $7.4 Million of BioNTech Stock | The Motley Fool

5 Best Biotech ETFs for 2026 and How to Invest | The Motley Fool

Also Discussed

ARK Genomic Revolution ETF

Company Information

Location

Cathie Wood's ARK Invest Adds Nvidia Stake, Sells AMD Stock Across Four ETFs

ARKG: Caught In The Tech Sell-Off, But Here's Why The Dip Is Buyable (BATS:ARKG)

Cathie Wood Just Bet Big on This Biotech Stock | The Motley Fool

Cathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy? | The Motley Fool

Cathie Wood's Ark Invest Sold $7.4 Million of BioNTech Stock | The Motley Fool

5 Best Biotech ETFs for 2026 and How to Invest | The Motley Fool

Also Discussed

Social

Sep 24

Bullish· Sep 17

Bearish· Aug 27

Macro· Dec 1

Technical Analysis· Aug 19

Regulars· Aug 19

Newcomers· Jun 27